China Traditional Chinese Medicine Holdings Co ( (CHIZF) ) has released its Q4 earnings. Here is a breakdown of the information China Traditional Chinese Medicine Holdings Co presented to its investors.
China Traditional Chinese Medicine Holdings Co. Limited, a key player in the Traditional Chinese Medicine (TCM) sector, specializes in the integration of Chinese medicinal herbs, TCM decoction pieces, concentrated TCM granules, finished drugs, and great health products. The company is known for its extensive network of medicinal herb bases and its commitment to innovation and sustainability in the TCM industry.
In its latest earnings report for the year ending December 31, 2024, China Traditional Chinese Medicine Holdings Co. Limited announced a decline in revenue and profit, attributed to various industry challenges and market competition. The company’s revenue decreased by 8.9% to RMB 16.51 billion, while net profit plummeted by 98.5% to RMB 20.77 million. Despite these setbacks, the company maintained a stable production and sales scale in its core business segments.
Key financial metrics revealed a mixed performance across different business segments. While the TCM decoction pieces and finished drugs segments saw revenue increases of 17.9% and 14.0%, respectively, the Chinese medicinal herbs integration and concentrated TCM granules segments experienced significant declines. The gross profit margin also decreased to 47.6% from 51.2% in the previous year.
Looking ahead, the company remains optimistic about overcoming short-term performance fluctuations, with a focus on corporate transformation, innovation, and sustainable development. The management is committed to enhancing the company’s core competitiveness and comprehensive strength through strategic reforms and resource integration.
China Traditional Chinese Medicine Holdings Co. Limited is poised to navigate the evolving TCM landscape with a strategic focus on reform, innovation, and efficiency improvements, aiming to consolidate its market position and drive long-term growth.